Diffusion Pharmaceuticals Inc. - DFFN STOCK NEWS

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) has scheduled its 2021 Annual Meeting for June 25, 2021, at 1 p.m. EDT. The meeting will be conducted virtually, allowing stockholders to vote and submit questions online. Stockholders, who were recorded as of May 5, 2021, are urged to review proxy materials and participate. Diffusion Pharmaceuticals focuses on innovative therapies for oxygen delivery in hypoxic conditions, with its lead candidate TSC aimed at addressing low oxygen levels in tissues. Further details on voting and attendance are outlined in the proxy materials.

Diffusion Pharmaceuticals (NASDAQ: DFFN) announced final results from its Phase 1b study of trans sodium crocetinate (TSC) in hospitalized COVID-19 patients. The independent Safety Monitoring Committee reviewed the data, affirming TSC's safety with more frequent dosing. Secondary endpoint analyses indicated improved outcomes for patients receiving higher doses, though the study was not aimed at evaluating efficacy. Diffusion plans further trials, including the TCOM trial with doses up to 2.5 mg/kg, to support future regulatory applications.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) announced its financial results for Q1 2021, showcasing a robust balance sheet bolstered by a $34.5 million equity raise. The company advanced its development of trans sodium crocetinate (TSC) with successful Phase 1 trials and significant cash reserves of approximately $46.6 million. R&D expenses rose to $2.9 million, largely due to ongoing trials, while general and administrative costs increased to $1.7 million. Key data from ongoing trials is expected in Q2 2021, guiding future clinical strategies aimed at oxygen delivery improvements.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) has completed enrollment in its Phase 1 trial of trans sodium crocetinate (TSC), a novel oxygen-enhancing therapy. The trial, involving 30 volunteers, aims to study TSC's impact on peripheral tissue oxygenation using transcutaneous oxygen monitoring (TCOM) devices. Results are expected in Q2 2021. Following this, two additional Oxygenation Trials are set for Q3 2021, focusing on hypoxia and lung diffusion efficiency. Positive outcomes from these trials could lead to further clinical studies in 2022.

On March 18, 2021, Diffusion Pharmaceuticals (NASDAQ: DFFN) announced the dosing of the first participants in its Phase 1 trial for the oxygen-enhancing therapeutic, trans sodium crocetinate (TSC). The trial will assess TSC's impact on peripheral tissue oxygenation using a transcutaneous oxygen monitoring device. This study is one of three planned oxygenation trials for 2021. Results aim to establish a dose-response relationship between TSC exposure and oxygenation, which will inform future development and commercialization strategies.

Diffusion Pharmaceuticals (NASDAQ: DFFN) reported significant advancements in its clinical development and financial position in 2020 and early 2021. The company appointed a new management team, initiated a Phase 1b trial for its lead product, trans sodium crocetinate (TSC), in hospitalized COVID-19 patients, and raised $36.7 million in early 2021. By March 2021, Diffusion had $36.7 million in cash, enhancing its financial stability and ability to conduct further trials. Three new oxygenation trials are set to evaluate TSC's efficacy, with expectations of demonstrating its beneficial impacts on oxygenation.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) announced that CEO Robert J. Cobuzzi, Ph.D., will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will cover recent corporate achievements, planned clinical trials, and potential milestones. Attendees can access the presentation on demand during the event. Diffusion is focused on developing therapies to enhance oxygen delivery to tissues, with its lead product candidate, trans sodium crocetinate (TSC), addressing hypoxia in various medical conditions.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) announced that the underwriter for its public offering exercised its option to purchase an additional 4,390,244 shares at $1.025 per share, raising gross proceeds of approximately $34.5 million. The funds will support research and development for its lead product candidate, trans sodium crocetinate, and other clinical trials. This offering was made under a shelf registration statement filed with the SEC.

Diffusion Pharmaceuticals (NASDAQ: DFFN) has successfully closed an underwritten public offering of 29,268,294 shares at $1.025 per share, generating approximately $30 million in gross proceeds. The offering allows the underwriter, H.C. Wainwright & Co., a 30-day option to purchase up to an additional 4,390,244 shares. The funds will be directed towards research and development for its lead product candidate, trans sodium crocetinate, and general corporate purposes. The shares were offered under an effective registration statement.